OA11.06 Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung 1

Expression (computer science) Line (geometry)
DOI: 10.1016/j.jtho.2024.09.064 Publication Date: 2024-10-16T02:33:01Z